Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase

Archives of Dermatological Research

Volumn 300, Issue 9, 2008, Pages 505-516

  Forsberg, Sofi ^a   Östman, Arne ^b   Rollman, Ola ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Epidermal growth factor; Epidermis; Psoriasis; Tyrosine kinase inhibitors

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CP 654577; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CELL FREE SYSTEM; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DERMIS; DRUG EFFECT; DRUG POTENCY; DRUG SPECIFICITY; EPIDERMIS; EPITHELIZATION; EXPLANT; FLUORESCENCE ANALYSIS; HISTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PSORIASIS; SKIN CULTURE; SKIN STRUCTURE; TISSUE REGENERATION; WESTERN BLOTTING;

CELL PROLIFERATION; CELLS, CULTURED; DERMIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; EPIDERMIS; HUMANS; KERATINOCYTES; MODELS, BIOLOGICAL; ORGAN CULTURE TECHNIQUES; PROTEIN-TYROSINE KINASES; PSORIASIS; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REGENERATION;

EID: 52549084857     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-008-0853-2     Document Type: Article

References (53)

1. J Albanell F Rojo S Averbuch A Feyereislova JM Mascaro R Herbst P LoRusso D Rischin S Sauleda J Gee RI Nicholson J Baselga 2002 Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 110 124
2. EG Barbacci LR Pustilnik AM Rossi E Emerson PE Miller BP Boscoe ED Cox KK Iwata JP Jani K Provoncha JC Kath Z Liu JD Moyer 2003 The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells Cancer Res 63 4450 4459
3. J Baselga 2002 Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 Suppl 4 2 8
4. H Ben-Bassat DV Vardi A Gazit SN Klaus M Chaouat Z Hartzstark A Levitzki 1995 Tyrphostins suppress the growth of psoriatic keratinocytes Exp Dermatol 4 82 88
5. H Ben-Bassat BY Klein 2000 Inhibitors of tyrosine kinases in the treatment of psoriasis Curr Pharm Des 6 933 942
6. BA Bernard SM Robinson S Vandaele JN Mansbridge M Darmon 1985 Abnormal maturation pathway of keratinocytes in psoriatic skin Br J Dermatol 112 647 653
7. R Bertrand E Solary P O'Connor KW Kohn Y Pommier 1994 Induction of a common pathway of apoptosis by staurosporine Exp Cell Res 211 314 321
8. M Bhushan B McLaughlin JB Weiss CE Griffiths 1999 Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis Br J Dermatol 141 1054 1060
9. PW Cook MR Pittelkow WW Keeble R Graves-Deal RJ Coffey Jr GD Shipley 1992 Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas Cancer Res 52 3224 3227
10. M Detmar LF Brown KP Claffey KT Yeo O Kocher RW Jackman B Berse HF Dvorak 1994 Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis J Exp Med 180 1141 1146
11. JT Elder GJ Fisher PB Lindquist GL Bennett MR Pittelkow RJ Coffey Jr L Ellingsworth R Derynck JJ Voorhees 1989 Overexpression of transforming growth factor alpha in psoriatic epidermis Science 243 811 814
12. S Forsberg U Saarialho-Kere O Rollman 2006 Comparison of growth-inhibitory agents by fluorescence imaging of human skin re-epithelialization in vitro Acta Derm Venereol 86 292 299
13. AB Gottlieb CK Chang DN Posnett B Fanelli JP Tam 1988 Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes J Exp Med 167 670 675
14. LG Hudson LJ McCawley 1998 Contributions of the epidermal growth factor receptor to keratinocyte motility Microsc Res Tech 43 444 455
15. CK Jiang T Magnaldo M Ohtsuki IM Freedberg F Bernerd M Blumenberg 1993 Epidermal growth factor and transforming growth factor alpha specifically induce the activation- and hyperproliferation-associated keratins 6 and 16 Proc Natl Acad Sci USA 90 6786 6790
16. I Johnson 1998 Fluorescent probes for living cells Histochem J 30 123 140
17. M Jost R Class C Kari PJ Jensen U Rodeck 1999 A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands J Invest Dermatol 112 443 449
18. LE King Jr RE Gates CM Stoscheck LB Nanney 1990 Epidermal growth factor/transforming growth factor alpha receptors and psoriasis J Invest Dermatol 95 10S 12S
19. G Krahn U Leiter P Kaskel M Udart J Utikal G Bezold RU Peter 2001 Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer Eur J Cancer 37 251 259
20. E Lee SH Jeon JY Yi YJ Jin YS Son 2001 Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation Biochem Biophys Res Commun 284 419 425
21. MW Lee CW Seo SW Kim HJ Yang HW Lee JH Choi KC Moon JK Koh 2004 Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor Acta Derm Venereol 84 23 26
22. IM Leigh H Navsaria PE Purkis IA McKay PE Bowden PN Riddle 1995 Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro Br J Dermatol 133 501 511
23. A Levitzki A Gazit 1995 Tyrosine kinase inhibition: an approach to drug development Science 267 1782 1788
24. H Lu O Rollman 2004 Fluorescence imaging of reepithelialization from skin explant cultures on acellular dermis Wound Repair Regen 12 575 586
25. F Mascia V Mariani G Girolomoni S Pastore 2003 Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation Am J Pathol 163 303 312
26. E Maubec P Duvillard V Velasco B Crickx MF Avril 2005 Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin Anticancer Res 25 1205 1210
27. V Mils N Basset-Seguin JP Moles A Tesniere I Leigh JJ Guilhou 1994 Comparative analysis of normal and psoriatic skin both in vivo and in vitro Differentiation 58 77 86
28. S Miyagawa H Fujimoto S Ko S Hirota Y Kitamura 2002 Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour Br J Dermatol 147 406 407
29. LB Nanney JA McKanna CM Stoscheck G Carpenter LE King 1984 Visualization of epidermal growth factor receptors in human epidermis J Invest Dermatol 82 165 169
30. LB Nanney CM Stoscheck M Magid LE King Jr 1986 Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis J Invest Dermatol 86 260 265
31. D Peus L Hamacher MR Pittelkow 1997 EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation J Invest Dermatol 109 751 756
32. M Piepkorn 1996 Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases Am J Dermatopathol 18 165 171
33. M Piepkorn MR Pittelkow PW Cook 1998 Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors J Invest Dermatol 111 715 721
34. M Piepkorn H Predd R Underwood P Cook 2003 Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes Arch Dermatol Res 295 93 101
35. Pinheiro JC, Bates DM (2000) Mixed-effects models in S and S-PLUS. Springer, New York
36. GD Plowman JM Culouscou GS Whitney JM Green GW Carlton L Foy MG Neubauer M Shoyab 1993 Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family Proc Natl Acad Sci USA 90 1746 1750
37. TJ Powell H Ben-Bassat BY Klein H Chen N Shenoy J McCollough B Narog A Gazit Z Harzstark M Chaouat R Levitzki C Tang J McMahon L Shawver A Levitzki 1999 Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors Br J Dermatol 141 802 810
38. MF Press C Cordon-Cardo DJ Slamon 1990 Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5 953 962
39. SA Prigent NR Lemoine CM Hughes GD Plowman C Selden WJ Gullick 1992 Expression of the c-erbB-3 protein in normal human adult and fetal tissues Oncogene 7 1273 1278
40. M Regnier D Asselineau MC Lenoir 1990 Human epidermis reconstructed on dermal substrates in vitro: an alternative to animals in skin pharmacology Skin Pharmacol 3 70 85
41. K Rikimaru JP Moles FM Watt 1997 Correlation between hyperproliferation and suprabasal integrin expression in human epidermis reconstituted in culture Exp Dermatol 6 214 221
42. S Segaert E Van Cutsem 2005 Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann Oncol 16 1425 1433
43. WJ Slichenmyer WL Elliott DW Fry 2001 CI-1033, a pan-erbB tyrosine kinase inhibitor Semin Oncol 28 80 85
44. R Srinivasan R Poulsom HC Hurst WJ Gullick 1998 Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types J Pathol 185 236 245
45. SW Stoll S Kansra S Peshick DW Fry WR Leopold JF Wiesen M Sibilia T Zhang Z Werb R Derynck EF Wagner JT Elder 2001 Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes Neoplasia 3 339 350
46. P Traxler G Bold E Buchdunger G Caravatti P Furet P Manley T O'Reilly J Wood J Zimmermann 2001 Tyrosine kinase inhibitors: from rational design to clinical trials Med Res Rev 21 499 512
47. P Traxler 2003 Tyrosine kinases as targets in cancer therapy-successes and failures Expert Opin Ther Targets 7 215 234
48. P Traxler PR Allegrini R Brandt J Brueggen R Cozens D Fabbro K Grosios HA Lane P McSheehy J Mestan T Meyer C Tang M Wartmann J Wood G Caravatti 2004 AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 4931 4941
49. J Varani H Lateef K Fay JT Elder 2005 Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin Skin Pharmacol Physiol 18 123 131
50. AE Wakeling SP Guy JR Woodburn SE Ashton BJ Curry AJ Barker KH Gibson 2002 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy Cancer Res 62 5749 5754
51. S Watanabe K Wagatsuma E Ichikawa H Takahashi 1991 Abnormal distribution of epidermal protein antigens in psoriatic epidermis J Dermatol 18 143 151
52. E Wierzbicka JM Tourani G Guillet 2006 Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 155 213 214
53. TA Wilgus AM Matthies KA Radek JV Dovi AL Burns R Shankar LA DiPietro 2005 Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes Am J Pathol 167 1257 1266